Therefore, these collective findings suggest that both of TGFβ2-treated or DEX-treated 3D HTM spheroids may rationally be applicable as in vitro POAG or SG models, respectively, for studies of the pathogenic conditions of the HTM observed in POAG or SG as well as the pharmacological effects of several anti-glaucoma drugs toward these HTM. The gene discussed is TGFB2; the disease is open-angle glaucoma.